« Return to News | Awards & Advancement

MicroConstants expands biomarker testing and analysis services

Wednesday, July 3, 2013 02:23 PM

MicroConstants, a CRO specializing in regulated bioanalysis and DMPK, has appointed Doinita Serban, Ph.D., director of biomarker research to oversee the expansion of biomarker testing and analysis services for preclinical and clinical diagnostic research. Doinita's experience with biomarker assay development, validation and profiling of disease panels, coupled with the implementation of the Luminex platform, will enable MicroConstants to broaden its biomarker analysis capabilities to include additional assay formats, such as multiplex immunoassays, gene expression and profiling assays.

Doinita brings more than 15 years of experience in the pharmaceutical industry, specializing in cancer and vascular biology, immunology and bioanalysis in preclinical and clinical research. She has spent over 10 years developing and validating biomarker assays for biopharmaceuticals on a variety of instrumentation platforms to support clinical diagnostic research for therapeutic areas including oncology, inflammation, infectious and vascular diseases.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.